Skip to content
%1$s Profile Image

Prize4Life, Inc.

Prize4Life is a results-driven nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for Amyotrophic Lateral Sclerosis (ALS). Tax ID 20-5055664


About Prize4Life

Central to our work is a drive to generate new ideas, foster new research, and drive innovation that creates opportunities for breakthroughs in the pursuit of a cure for ALS. We are determined to eradicate ALS by catalyzing new ideas, eliminating barriers, and generating results.


Founded in 2006 by Avichai Kremer, who was diagnosed with ALS while a Harvard Business School student at age 29.  We believe that solutions to some of the biggest challenges in ALS research will require out-of-the-box thinking, and that some of the most critical discoveries may come from unlikely places. To that end, our programs and initiatives focus on a prize-for-breakthrough model that provides both financial and other incentives for advancing progress on the path to a cure. For more information, visit



Our Challenge


ALS, more commonly known as Lou Gehrig’s disease, is a progressive, fatal, neurodegenerative disease that attacks motor neurons.  When motor neurons die, the brain is no longer able to control muscle movement.  Unable to function, muscles atrophy.  Eventually, all muscles under voluntary control are affected and patients in time lose their ability to move, speak, swallow, or breathe on their own.  During this process, the brain typically remains intact allowing the patient to anticipate and observe the loss of each function. 


There are more than 600,000 people around the world suffering from ALS. The majority of whom will die within two to five years of diagnosis.  At present, there is no cure or effective treatment for this indiscriminate, merciless illness. 


Our Impact

To address this challenge, we have developed a series of prizes and ongoing programs that offer both financial incentives and material support for ALS research. Prize4Life’s programs already have yielded key results setting the stage for significant progress in the fight against ALS.